肿瘤细胞治疗研究
英文原题：How I Approach Treatment of Relapsed Acute Lymphoblastic Leukemia in Patients With Down Syndrome.
How I Approach Treatment of Relapsed Acute Lymphoblastic Leukemia in Patients With Down Syndrome.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
唐氏综合征（DS）患儿在急性淋巴细胞白血病（ALL）治疗期间，因感染性并发症而出现过高的治疗相关死亡率（TRM）。
唐氏综合征（DS）患儿在急性淋巴细胞白血病（ALL）治疗期间，因感染并发症导致过高的治疗相关死亡率（TRM）。在治疗ALL复发所需的强化化疗期间，这一风险进一步增加，限制了传统强化复发化疗的可行性。抗分化簇19（CD19）嵌合抗原受体（CAR）T细胞疗法是DS合并复发性B-ALL患儿（包括首次复发者）的一种新兴治疗选择。该方法已显示出良好的疗效，同时可能降低与强化挽救化疗相关的TRM。强烈鼓励DS合并复发性B-ALL患者接受这种形式的免疫治疗。
Children with Down syndrome (DS) experience excessive treatment-related mortality (TRM), primarily due to infectious complications, during treatment for acute lymphoblastic leukemia (ALL). This risk further increases during the intensive chemotherapy required to treat a relapse of ALL, limiting the feasibility of conventional intensive relapse chemotherapy. Anti-cluster of differentiation 19 (CD19) chimeric antigen receptor (CAR) T-cell therapy is an emerging treatment option for children with DS and relapsed B-ALL, including those in first relapse. This approach has demonstrated promising efficacy while potentially reducing the TRM associated with intensive salvage chemotherapy. Access to this form of immunotherapy for patients with DS and relapsed B-ALL is strongly encouraged.
MEMBER ACCOUNT
登录成功会直接打开下一页。
